Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The antibody response in HIV-1-infected donors

The antibody response in HIV-1-infected donors Purpose of review Although the goal of preventive HIV vaccine design is primarily the induction of broadly neutralizing antibodies (bNAbs), recent evidence suggests that a protective response will also benefit from Fc effector functions. Here, we provide an update on the antibody response to HIV infection, including both Fab and Fc-mediated antibody responses. We also highlight recent studies showing the interplay between these functions, focusing primarily on studies published in the last year. Recent findings Identification and characterization of bNAb donors continues to provide insights into viral factors that are potentially translatable to vaccine design. Improved and more diverse measures of Fc effector function, and modulators thereof, are enabling a deeper understanding of their role in infection. New data providing mechanistic links between the innate and adaptive humoral immune responses are creating exciting opportunities for vaccine strategies, with the aim of eliciting a polyfunctional protective response. Summary New insights into the overall humoral response to HIV infection are defining diverse and synergistic mechanisms required for antibody protection from HIV through vaccination. aCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service bFaculty of Health Sciences, University of the Witwatersrand, Johannesburg cCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa Correspondence to Penny L. Moore, Centre for HIV and STIs, National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa. Tel: +27 11 386 6331; fax: +27 11 386 6333; e-mail: pennym@nicd.ac.za http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

The antibody response in HIV-1-infected donors

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/the-antibody-response-in-hiv-1-infected-donors-sJ8CY6o4eY

References (54)

Publisher
Wolters Kluwer Health
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000559
Publisher site
See Article on Publisher Site

Abstract

Purpose of review Although the goal of preventive HIV vaccine design is primarily the induction of broadly neutralizing antibodies (bNAbs), recent evidence suggests that a protective response will also benefit from Fc effector functions. Here, we provide an update on the antibody response to HIV infection, including both Fab and Fc-mediated antibody responses. We also highlight recent studies showing the interplay between these functions, focusing primarily on studies published in the last year. Recent findings Identification and characterization of bNAb donors continues to provide insights into viral factors that are potentially translatable to vaccine design. Improved and more diverse measures of Fc effector function, and modulators thereof, are enabling a deeper understanding of their role in infection. New data providing mechanistic links between the innate and adaptive humoral immune responses are creating exciting opportunities for vaccine strategies, with the aim of eliciting a polyfunctional protective response. Summary New insights into the overall humoral response to HIV infection are defining diverse and synergistic mechanisms required for antibody protection from HIV through vaccination. aCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service bFaculty of Health Sciences, University of the Witwatersrand, Johannesburg cCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa Correspondence to Penny L. Moore, Centre for HIV and STIs, National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa. Tel: +27 11 386 6331; fax: +27 11 386 6333; e-mail: pennym@nicd.ac.za

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Jul 1, 2019

There are no references for this article.